Co-Authors
This is a "connection" page, showing publications co-authored by Arturo Ciccullo and Simona Di Giambenedetto.
Connection Strength
5.469
-
The need to continue testing for HIV, even during the coronavirus disease 2019 (COVID-19) pandemic. HIV Med. 2021 01; 22(1):e3-e4.
Score: 0.901
-
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice. Infez Med. 2018 Dec 01; 26(4):336-340.
Score: 0.798
-
An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy. HIV Med. 2018 07; 19(6):369-375.
Score: 0.753
-
Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak. Diagnostics (Basel). 2021 Jun 24; 11(7).
Score: 0.238
-
Determinants of SARS-COV-2 seroconversion in a cohort of recovered patients. Infez Med. 2021 Mar 01; 29(1):163-164.
Score: 0.233
-
No evidence of SARS-CoV-2 circulation in HIV-infected patients between December 2019 and February 2020 in Rome, Italy. Clin Microbiol Infect. 2020 Dec 02.
Score: 0.229
-
Still Much to Learn About the Diagnostic Role of SARS-CoV-2 Antibody Detection. Clin Infect Dis. 2020 11 19; 71(16):2299-2300.
Score: 0.229
-
SARS-CoV-2 infection in a highly experienced person living with HIV. AIDS. 2020 07 01; 34(8):1257-1258.
Score: 0.223
-
Off-label use of tocilizumab in patients with SARS-CoV-2 infection. J Med Virol. 2020 10; 92(10):1787-1788.
Score: 0.222
-
Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line. Int J Antimicrob Agents. 2020 Aug; 56(2):106017.
Score: 0.220
-
COVID-19 diagnosis does not rule out other concomitant diseases. Eur J Clin Invest. 2020 Jun; 50(6):e13241.
Score: 0.220
-
Efficacy and safety of raltegravir in switch strategies in virologically suppressed patients: long-term data from clinical practice. J Antimicrob Chemother. 2019 08 01; 74(8):2470-2472.
Score: 0.209
-
Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice. J Antimicrob Chemother. 2019 05 01; 74(5):1461-1463.
Score: 0.205
-
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice. BMC Infect Dis. 2019 Jan 17; 19(1):59.
Score: 0.201
-
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART. J Clin Virol. 2018 06; 103:57-62.
Score: 0.190
-
Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication. HIV Med. 2018 Mar 24.
Score: 0.190
-
People Living with HIV in the COVID-19 Era: A Case Report. AIDS Res Hum Retroviruses. 2021 04; 37(4):253-254.
Score: 0.056
-
Derivation and validation of a scoring system to assess pre-test probability of being COVID-19 positive. J Infect. 2021 01; 82(1):159-198.
Score: 0.055
-
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy. J Antimicrob Chemother. 2018 07 01; 73(7):1949-1954.
Score: 0.048
-
Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study. Open Forum Infect Dis. 2018 Jun; 5(6):ofy113.
Score: 0.048